- Home
- MCRB vs KF Comparison
MCRB vs KF Comparison
Compare MCRB & KF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- KF
- Stock Information
- Founded
- MCRB 2010
- KF 1984
- Country
- MCRB United States
- KF United States
- Employees
- MCRB N/A
- KF N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- KF Investment Managers
- Sector
- MCRB Health Care
- KF Finance
- Exchange
- MCRB Nasdaq
- KF Nasdaq
- Market Cap
- MCRB 156.3M
- KF 93.8M
- IPO Year
- MCRB 2015
- KF N/A
- Fundamental
- Price
- MCRB $0.84
- KF $18.49
- Analyst Decision
- MCRB Buy
- KF
- Analyst Count
- MCRB 4
- KF 0
- Target Price
- MCRB $5.63
- KF N/A
- AVG Volume (30 Days)
- MCRB 2.4M
- KF 18.4K
- Earning Date
- MCRB 11-13-2024
- KF 01-01-0001
- Dividend Yield
- MCRB N/A
- KF N/A
- EPS Growth
- MCRB N/A
- KF N/A
- EPS
- MCRB N/A
- KF N/A
- Revenue
- MCRB $126,325,000.00
- KF N/A
- Revenue This Year
- MCRB N/A
- KF N/A
- Revenue Next Year
- MCRB N/A
- KF N/A
- P/E Ratio
- MCRB N/A
- KF N/A
- Revenue Growth
- MCRB 12856.41
- KF N/A
- 52 Week Low
- MCRB $0.54
- KF $18.30
- 52 Week High
- MCRB $2.05
- KF $25.56
- Technical
- Relative Strength Index (RSI)
- MCRB 47.60
- KF 28.36
- Support Level
- MCRB $0.80
- KF $18.43
- Resistance Level
- MCRB $1.00
- KF $19.60
- Average True Range (ATR)
- MCRB 0.06
- KF 0.34
- MACD
- MCRB -0.01
- KF -0.08
- Stochastic Oscillator
- MCRB 20.46
- KF 7.57
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About KF Korea Fund Inc. (The) New
Korea Fund Inc is a closed-end, non-diversified management investment company. Its investment objective is to seek long-term capital appreciation through investment in securities, equity securities, of Korean companies. Its portfolio consists of the different sectors such as the auto components, banks, beverages, chemicals, aerospace and defense, insurance, machinery, and others.